Meeting
2022 ASCO Genitourinary Cancers Symposium
Distribution of immune-related adverse events (irAEs) across genitourinary (GU) malignancies.
Authors
Nataliya Mar
University of California Irvine, Orange, CA
Nataliya Mar , Matthew Slaught , Dalia Kaakour , Armon Azizi , Jennifer Brooke Valerin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 480)
DOI
10.1200/JCO.2022.40.6_suppl.480
Abstract #
480
Poster Bd #
E2
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Immune-related adverse events (irAE) in GU cancer patients receiving immune checkpoint inhibitors.
First Author: Peter Zang
First Author: Jeddeo Paul
Poster
2024 ASCO Genitourinary Cancers Symposium
Regulatory approvals for genitourinary (GU) cancer by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) over 20 years (2003-2023).
First Author: Sanjay Khanna
Poster
2023 ASCO Annual Meeting
Safety of checkpoint inhibitors in older patients with genitourinary cancers.
First Author: Brian Hemendra Ramnaraign